Cargando…
Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial
BACKGROUND: Two most important factors determining treatment success in chronic myeloid leukemia (CML) are adequate medication compliance and molecular monitoring albeit still being suboptimal. The CMyLife platform is an eHealth innovation, co-created with and for CML patients, aiming to improve the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994406/ https://www.ncbi.nlm.nih.gov/pubmed/36890512 http://dx.doi.org/10.1186/s12913-023-09153-9 |
_version_ | 1784902625518419968 |
---|---|
author | Verweij, Lynn Ector, Geneviève I. C. G. Smit, Yolba van Vlijmen, Bas van der Reijden, Bert A. Hermens, Rosella P. M. G. Blijlevens, Nicole M. A. |
author_facet | Verweij, Lynn Ector, Geneviève I. C. G. Smit, Yolba van Vlijmen, Bas van der Reijden, Bert A. Hermens, Rosella P. M. G. Blijlevens, Nicole M. A. |
author_sort | Verweij, Lynn |
collection | PubMed |
description | BACKGROUND: Two most important factors determining treatment success in chronic myeloid leukemia (CML) are adequate medication compliance and molecular monitoring albeit still being suboptimal. The CMyLife platform is an eHealth innovation, co-created with and for CML patients, aiming to improve their care, leading to an increased quality of life and the opportunity of hospital-free care. OBJECTIVE: To explore the effectiveness of CMyLife in terms of information provision, patient empowerment, medication compliance, molecular monitoring, and quality of life. METHODS: Effectiveness of CMyLife was explored using a patient-preference trial. Upon completion of the baseline questionnaire, participants actively used (intervention group) or did not actively use (questionnaire group) the CMyLife platform for at least 6 months, after which they completed the post-intervention questionnaire. Scores between the intervention group and the questionnaire group were compared with regard to the within-subject change between baseline and post-measurement using Generalized Estimating Equation models. RESULTS: At baseline, 33 patients were enrolled in the questionnaire group and 75 in the intervention group. Online health information knowledge improved significantly when actively using CMyLife and patients felt more empowered. No significant improvements were found regarding medication compliance and molecular monitoring, which were already outstanding. Self-reported effectiveness showed that patients experienced that using CMyLife improved their medication compliance and helped them to oversee their molecular monitoring. Patients using CMyLife reported more symptoms but were better able to manage these. CONCLUSIONS: Since hospital-free care has shown to be feasible in time of the COVID-19 pandemic, eHealth-based innovations such as CMyLife could be a solution to maintain the quality of care and make current oncological health care services more sustainable. TRIAL REGISTRATION: ClinicalTrials.gov NCT04595955, 22/10/2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-09153-9. |
format | Online Article Text |
id | pubmed-9994406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99944062023-03-09 Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial Verweij, Lynn Ector, Geneviève I. C. G. Smit, Yolba van Vlijmen, Bas van der Reijden, Bert A. Hermens, Rosella P. M. G. Blijlevens, Nicole M. A. BMC Health Serv Res Research BACKGROUND: Two most important factors determining treatment success in chronic myeloid leukemia (CML) are adequate medication compliance and molecular monitoring albeit still being suboptimal. The CMyLife platform is an eHealth innovation, co-created with and for CML patients, aiming to improve their care, leading to an increased quality of life and the opportunity of hospital-free care. OBJECTIVE: To explore the effectiveness of CMyLife in terms of information provision, patient empowerment, medication compliance, molecular monitoring, and quality of life. METHODS: Effectiveness of CMyLife was explored using a patient-preference trial. Upon completion of the baseline questionnaire, participants actively used (intervention group) or did not actively use (questionnaire group) the CMyLife platform for at least 6 months, after which they completed the post-intervention questionnaire. Scores between the intervention group and the questionnaire group were compared with regard to the within-subject change between baseline and post-measurement using Generalized Estimating Equation models. RESULTS: At baseline, 33 patients were enrolled in the questionnaire group and 75 in the intervention group. Online health information knowledge improved significantly when actively using CMyLife and patients felt more empowered. No significant improvements were found regarding medication compliance and molecular monitoring, which were already outstanding. Self-reported effectiveness showed that patients experienced that using CMyLife improved their medication compliance and helped them to oversee their molecular monitoring. Patients using CMyLife reported more symptoms but were better able to manage these. CONCLUSIONS: Since hospital-free care has shown to be feasible in time of the COVID-19 pandemic, eHealth-based innovations such as CMyLife could be a solution to maintain the quality of care and make current oncological health care services more sustainable. TRIAL REGISTRATION: ClinicalTrials.gov NCT04595955, 22/10/2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-09153-9. BioMed Central 2023-03-08 /pmc/articles/PMC9994406/ /pubmed/36890512 http://dx.doi.org/10.1186/s12913-023-09153-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Verweij, Lynn Ector, Geneviève I. C. G. Smit, Yolba van Vlijmen, Bas van der Reijden, Bert A. Hermens, Rosella P. M. G. Blijlevens, Nicole M. A. Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial |
title | Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial |
title_full | Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial |
title_fullStr | Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial |
title_full_unstemmed | Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial |
title_short | Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial |
title_sort | effectiveness of digital care platform cmylife for patients with chronic myeloid leukemia: results of a patient-preference trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994406/ https://www.ncbi.nlm.nih.gov/pubmed/36890512 http://dx.doi.org/10.1186/s12913-023-09153-9 |
work_keys_str_mv | AT verweijlynn effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial AT ectorgenevieveicg effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial AT smityolba effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial AT vanvlijmenbas effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial AT vanderreijdenberta effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial AT hermensrosellapmg effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial AT blijlevensnicolema effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial |